Trials / Completed
CompletedNCT01472770
A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Vejle Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The present study aims to investigate the efficacy and safety of the combination of capecitabine and gemcitabine in heavily pre-treated, treatment resistant metastatic colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemcitabine + Capecitabine | Gemcitabine: 1000 mg/m2 intravenously over 30 min. on day 1 in 2-weeks cycles. Capecitabine: Peroral tablet 2000 mg/m2 daily on days 1-7 in 2-weeks cycles. |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2013-05-01
- Completion
- 2014-05-01
- First posted
- 2011-11-16
- Last updated
- 2014-12-04
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT01472770. Inclusion in this directory is not an endorsement.